Literature DB >> 12389640

Costimulatory molecules and autoimmune thyroid diseases.

Claudia Salmaso1, Daniel Olive, Giampaola Pesce, Marcello Bagnasco.   

Abstract

At least two signals for proliferation and cytokine secretion by T-cells are required. The first signal is delivered through the interaction of the T-cell receptor with major histocompatibility complex (MHC) molecules expressed on the surface of antigen-presenting cells (APC). The second or costimulatory signal is delivered by cell surface molecules expressed by APC. The interaction of B7.1/B7.2 with CD28 provide the most potent costimulatory signal for T-cell activation. CD40 antigen and its ligand (CD40L) have been shown to play a major role in regulating both humoral and cellular immune responses. In autoimmune thyroid diseases autoantigen presentation could be provided by "professional" APC, such as dendritic cells, as well as "nonprofessional" APC, such as thyroid follicular cells (TFC). In fact, these cells aberrantly express MHC class II molecules in Graves' disease (GD) and Hashimoto's thyroiditis (HT), together with large amounts of MHC class I antigens: moreover, the expression of CD40 on TFC, has been demonstrated. On the other hand B7.1 has been demonstrated in HT, but not in GD TFC. This could provide in HT a local costimulatory signal for T-cell differentiation towards a type 1 cytokine secretion pattern and also result in rescue from apoptosis of infiltrating lymphocytes. The presence of ICAM-1 on the surface of HT TFC may further strengthen contact and facilitate cross-signaling between T-cells and TFC. In contrast, the absence of B7 and ICAM-1 antigens in most GD TFC may more easily be associated with anergy and apoptosis of infiltrating T-cells, preventing the perpetuation and expansion of a "destructive" autoimmune reaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389640     DOI: 10.1080/08916930290013441

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  7 in total

1.  Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.

Authors:  İlknur Bingül; Pervin Vural; Semra Doğru-Abbasoğlu; Esra Çil; Müjdat Uysal
Journal:  J Clin Lab Anal       Date:  2016-12-07       Impact factor: 2.352

Review 2.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

3.  CD40 ligand induces expression of vascular cell adhesion molecule 1 and E-selectin in orbital fibroblasts from patients with Graves' orbitopathy.

Authors:  Hao Wang; Li-Shuang Zhu; Jin-Wei Cheng; Ji-Ping Cai; You Li; Xiao-Ye Ma; Rui-Li Wei
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-11       Impact factor: 3.117

4.  B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Authors:  Raymond S Douglas; Vibharavi Naik; Catherine J Hwang; Nikoo F Afifiyan; Andrew G Gianoukakis; Daniel Sand; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

5.  Dendritic cells infected with adenovirus expressing the thyrotrophin receptor induce Graves' hyperthyroidism in BALB/c mice.

Authors:  M Kita-Furuyama; Y Nagayama; P Pichurin; S M McLachlan; B Rapoport; K Eguchi
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

6.  CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.

Authors:  Edyta Pawlak-Adamska; Irena Frydecka; Marek Bolanowski; Anna Tomkiewicz; Anna Jonkisz; Lidia Karabon; Anna Partyka; Oskar Nowak; Marek Szalinski; Jacek Daroszewski
Journal:  Endocrine       Date:  2016-09-16       Impact factor: 3.633

7.  Polymorphisms of the ICAM-1 exon 6 (E469K) are associated with differentiation of colorectal cancer.

Authors:  Qing-lei Wang; Bing-hui Li; Bin Liu; Ya-bin Liu; Yue-Ping Liu; Sui-Bing Miao; Yi Han; Jin-Kun Wen; Mei Han
Journal:  J Exp Clin Cancer Res       Date:  2009-10-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.